Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Metabolon, Inc.
Biomarkers of Prostate Cancer Progression Identified with Biochemical Profiling Technology
February 24th, 2009
Metabolon, Inc., the leader in metabolomics-driven biomarker discovery and analysis, announced that the company’s global biochemical profiling technology has been used to identify biomarkers indicative of prostate cancer progression. The results of the study, conducted with researchers at the University of Michigan, will be published in the February 12 issue of Nature in a paper titled “Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression”. The study described in the Nature paper was undertaken to better understand and profile the metabolic changes associated with prostate cancer progression. Using Metabolon’s biochemical profiling...
Source: Cancer Weekly (2009-02-24)
|
